Alberto Magni
Overview
Explore the profile of Alberto Magni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Magni A, Agostoni P, Bonezzi C, Massazza G, Mene P, Savarino V, et al.
Pain Ther
. 2021 Apr;
10(2):783-808.
PMID: 33876393
Osteoarthritis (OA) is a leading cause of disability among older adults worldwide. Treatment aims are to alleviate inflammatory pain and improve physical function through non-pharmacological and pharmacological interventions. Non-steroidal anti-inflammatory...
12.
Bettiol A, Marconi E, Vannacci A, Simonetti M, Magni A, Cricelli C, et al.
Int J Clin Pharm
. 2021 Jan;
43(4):1045-1054.
PMID: 33411104
Background General practitioners often deal with patients suffering acute musculoskeletal disorders. Paracetamol, non-steroidal anti-inflammatory drugs, and opioids are the most prescribed medications, according to pain intensity and patient's features. Combinations...
13.
Bonezzi C, Fornasari D, Cricelli C, Magni A, Ventriglia G
Pain Ther
. 2020 Dec;
9(Suppl 1):17-28.
PMID: 33315207
Chronic pain is a public health priority that affects about 20% of the general population, causing disability and impacting productivity and quality of life. It is often managed in the...
14.
Bonezzi C, Fornasari D, Cricelli C, Magni A, Ventriglia G
Pain Ther
. 2020 Dec;
9(Suppl 1):1-15.
PMID: 33315206
Chronic pain is considered a public health priority by the World Health Organization and European health institutions. It has reached alarming proportions in terms of disability, consumption of health and...
15.
Margarit Ferri C, Natoli S, Sanz-Ayan P, Magni A, Guerrero C, Lara-Solares A, et al.
Pain Manag
. 2020 Nov;
11(2):173-187.
PMID: 33241725
To investigate quality of life (QOL) and functionality changes in chronic pain during tapentadol prolonged release (PR) treatment. analysis of data from three Phase III trials in patients with osteoarthritis...
16.
Lombardi N, Vannacci A, Bettiol A, Marconi E, Pecchioli S, Magni A, et al.
Clin Drug Investig
. 2019 Mar;
39(5):455-462.
PMID: 30852809
Background And Objectives: In 2014, the Italian Medicines Agency (AIFA) amended the summary of product characteristics of codeine-containing medications limiting their use for maximum three days. This study attempted to...
17.
Zanini B, Caselani F, Magni A, Turini D, Ferraresi A, Lanzarotto F, et al.
Clin Gastroenterol Hepatol
. 2012 Oct;
11(3):253-8.
PMID: 23022697
Background & Aims: Patients with celiac disease have varying degrees of damage to the small intestinal mucosa, ranging from lymphocytic duodenosis with normal villous structure to severe villous atrophy. We...
18.
Zanini B, Ricci C, Bandera F, Caselani F, Magni A, Laronga A, et al.
Am J Gastroenterol
. 2012 Apr;
107(6):891-9.
PMID: 22525306
Objectives: Post-infectious irritable bowel syndrome (PI-IBS) may develop in 4-31% of affected patients following bacterial gastroenteritis (GE), but limited information is available on long-term outcome of viral GE. During summer...
19.
Zanini B, Magni A, Caselani F, Lanzarotto F, Carabellese N, Villanacci V, et al.
Dig Liver Dis
. 2011 Nov;
44(4):280-5.
PMID: 22119616
Background: Duodenal biopsy may be unnecessary to confirm celiac disease in patients with high tissue-transglutaminase antibody level. Aims: To define a cut-off value of tissue-transglutaminase antibody with high positive likelihood...
20.
Zanchetti A, Crepaldi G, Bond M, Gallus G, Veglia F, Mancia G, et al.
Stroke
. 2004 Oct;
35(12):2807-12.
PMID: 15514192
Background And Purpose: The Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS) tested whether (1) the angiotensin-converting enzyme (ACE) inhibitor fosinopril (20 mg per day) was more effective on carotid atherosclerosis progression...